论文部分内容阅读
目的探讨消旋卡多曲颗粒联合蒙脱石散治疗婴幼儿轮状病毒肠炎的疗效。方法将临床确诊为婴幼儿轮状病毒肠炎患儿78例随机分为治疗组和对照组各39例。对照组予蒙脱石散、金双歧、保护胃肠黏膜、补液等综合治疗,治疗组在对照组综合治疗的基础上加用消旋卡多曲颗粒治疗,治疗72h后观察疗效。结果两组主要临床表现消失时间(大便次数正常时间和大便性状正常时间)治疗组分别为(2.71±0.16)d、(2.91±0.23)d,对照组分别为(3.08±0.29)d、(3.24±0.38)d,两组比较差异均有统计学意义(P<0.01)。治疗组总有效率为94.86%,对照组总有效率为76.91%,两组比较差异均有统计学意义(χ2=5.19,P<0.05)。治疗组平均住院时间(2.61±0.83)d、对照组平均住院时间(5.29±0.24)d,两组比较差异均有统计学意义(t=19.37,P<0.01)。结论消旋卡多曲颗粒联合蒙脱石散治疗婴幼儿轮状病毒肠炎疗效好,能明显缩短病程,迅速改善临床症状,且未发现与药物有关的不良反应,安全性好,值得临床广。
Objective To investigate the curative effect of racecadotril and montmorillonite in the treatment of infantile rotavirus enteritis. Methods 78 cases of infants with rotavirus enteritis diagnosed clinically were randomly divided into treatment group (39 cases) and control group (39 cases). The control group was treated with montmorillonite powder, gold bifidus, protective gastrointestinal mucosa, rehydration and other comprehensive treatment. The treatment group was treated with racecadotril granules on the basis of the comprehensive treatment in the control group. After 72 hours of treatment, the curative effect was observed. Results The disappearance time (normal stool frequency and normal stool stool time) in the two groups were (2.71 ± 0.16) days and (2.91 ± 0.23) days respectively in the treatment group and (3.08 ± 0.29) days and ± 0.38) d, the differences between the two groups were statistically significant (P <0.01). The total effective rate was 94.86% in the treatment group and 76.91% in the control group. The difference between the two groups was statistically significant (χ2 = 5.19, P <0.05). The average length of hospital stay in the treatment group was (2.61 ± 0.83) d, and the average length of stay in the control group was (5.29 ± 0.24) days. The differences between the two groups were statistically significant (t = 19.37, P <0.01). Conclusions Racecadotril granules combined with montmorillonite powder have a good curative effect on rotavirus enteritis in infants and young children. It can shorten the course of the disease and improve the clinical symptoms rapidly. No adverse reactions related to the drug are found, which is safe and worthy of clinical application.